Application of evidence-based dentistry: From research to clinical periodontal practice

Periodontology 2000

Volumn 59, Issue 1, 2012, Pages 61-74

  Kwok, Vivien ^a   Caton, Jack G ^a   Polson, Alan M ^a   Hunter, Paul G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA BASE; DECISION MAKING; DENTAL RESEARCH; EVIDENCE BASED DENTISTRY; HUMAN; INFORMATION LITERACY; INFORMATION RETRIEVAL; LITERATURE; META ANALYSIS (TOPIC); PATIENT CARE PLANNING; PERIODONTAL DISEASE;

DATABASES AS TOPIC; DECISION MAKING; DENTAL RESEARCH; EVIDENCE-BASED DENTISTRY; HUMANS; INFORMATION LITERACY; INFORMATION STORAGE AND RETRIEVAL; META-ANALYSIS AS TOPIC; PATIENT CARE PLANNING; PERIODONTAL DISEASES; REVIEW LITERATURE AS TOPIC;

EID: 84859865349     PISSN: 09066713     EISSN: 16000757     Source Type: Journal    
DOI: 10.1111/j.1600-0757.2011.00437.x     Document Type: Article

References (94)

1. Abitbol TE, Rosenfeld-Abitbol M. Surgical treatment of nifedipine-induced gingival hyperplasia. A case report. N Y State Dent J 1996: 62: 34-37.
2. American Dental Association. Center for Evidence-Based Dentistry. Available at: Accessed March 1, 2012.
3. American Dental Association. Available at: Accessed March 1, 2012.
4. Barak S, Kaplan I. The CO2 laser in the excision of gingival hyperplasia caused by nifedipine. J Clin Periodontol 1988: 15: 633-635.
5. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992: 19: 311-314.
6. Beaglehole R, Bonita R, Kjellstrom T. Basic epidemiology. Geneva: World Health Organization, 2006.
7. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000: 342: 1878-1886.
8. Brunet L, Miranda J, Farre M, Berini L, Mendieta C. Gingival enlargement induced by drugs. Drug Saf 1996: 15: 219-231.
9. Buduneli N, Buduneli E, Cinar S, Lappin D, Kinane DF. Immunohistochemical evaluation of Ki-67 expression and apoptosis in cyclosporin A-induced gingival overgrowth. J Periodontol 2007: 78: 282-289.
10. Bullon P, Machuca G, Armas JR, Rojas JL, Jimenez G. The gingival inflammatory infiltrate in cardiac patients treated with calcium antagonists. J Clin Periodontol 2001: 28: 897-903.
11. Bullon P, Machuca G, Martinez Sahuquillo A, Rojas J, Lacalle JR, Rios JV, Velasco E. Clinical assessment of gingival size among patients treated with diltiazem. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995: 79: 300-304.
12. Bullon P, Machuca G, Martinez-Sahuquillo A, Rios JV, Velasco E, Rojas J, Lacalle JR. Evaluation of gingival and periodontal conditions following causal periodontal treatment in patients treated with nifedipine and diltiazem. J Clin Periodontol 1996: 23: 649-657.
13. Bullon P, Pugnaloni A, Gallardo I, Machuca G, Hevia A, Battino M. Ultrastructure of the gingiva in cardiac patients treated with or without calcium channel blockers. J Clin Periodontol 2003: 30: 682-690.
14. Carr AB. Systematic reviews of the literature: the overview and meta-analysis. Dent Clin North Am 2002: 46: 79-86.
15. Cebeci I, Kantarci A, Firatli E, Aygün S, Tanyeri H, Aydin AE, Carin M, Güç U, Tuncer O. Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine-A. J Clin Periodontol 1996: 23: 737-742.
16. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009. Accessed March 1, 2012.
17. Coletta RD, Graner E. Hereditary gingival fibromatosis: a systematic review. J Periodontol 2006: 77: 753-764.
18. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000: 342: 1887-1892.
19. Daly B, Batchelor P, Treasure E. Essential dental public health. New York: Oxford University Press, 2002.
20. Darbar UR, Hopper C, Speight PM, Newman HN. Combined treatment approach to gingival overgrowth due to drug therapy. J Clin Periodontol 1996: 23: 941-944.
21. Davidovich E, Schwarz Z, Davidovitch M, Eidelman E, Bimstein E. Oral findings and periodontal status in children, adolescents and young adults suffering from renal failure. J Clin Periodontol 2005: 32: 1076-1082.
22. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004: 69: 548-556.
23. EBM Librarian. Appraising the evidence. Accessed March 1, 2012.
24. Ellis JS, Seymour RA, Monkman S, Idle JR. Disposition of nifedipine in plasma and gingival crevicular fluid in relation to drug-induced gingival overgrowth. J Periodontal Res 1993: 28: 373-378.
25. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol 1999: 70: 63-67.
26. Ellis JS, Seymour RA, Thomason JM, Butler TJ, Idle JR. Periodontal variables affecting nifedipine sequestration in gingival crevicular fluid. J Periodontal Res 1995: 30: 272-276.
27. Forrest JL, Miller SA. Translating evidence-based decision making into practice: EBDM concepts and finding the evidence. J Evid Based Dent Pract 2009: 9: 59-72.
28. Fujii A, Matsumoto H, Nakao S, Teshigawara H, Akimoto Y. Effect of calcium-channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders. Arch Oral Biol 1994: 39: 99-104.
29. Gillette J. Striving for excellence with evidence-based dentistry. J Evid Based Dent Pract 2009: 9: 125-128.
30. Giusto TJ. Periodontal management of gingival overgrowth in a renal transplant patient: a case report. J N J Dent Assoc 2005: 76: 26-29.
31. Hall EE. Prevention and treatment considerations in patients with drug-induced gingival enlargement. Curr Opin Periodontol 1997: 4: 59-63.
32. Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000 1999: 21: 176-196.
33. Hancock RH, Swan RH. Nifedipine-induced gingival overgrowth. Report of a case treated by controlling plaque. J Clin Periodontol 1992: 19: 12-14.
34. Hapak L. Periodontal management of nifedipine-induced gingival overgrowth: a case report and review of the pertinent literature. Oral Health quiz 22, 1994: 84: 15-17.
35. Harel-Raviv M, Eckler M, Lalani K, Raviv E, Gornitsky M. Nifedipine-induced gingival hyperplasia. A comprehensive review and analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995: 79: 715-722.
36. Huang WT, Lu HK, Chou HH, Kuo MYP. Immunohistochemical analysis of Th1/Th2 cytokine profiles and androgen receptor expression in the pathogenesis of nifedipine-induced gingival overgrowth. J Periodontal Res 2003: 38: 422-427.
37. Ikawa K, Ikawa M, Shimauchi H, Iwakura M, Sakamoto S. Treatment of gingival overgrowth induced by manidipine administration. A case report. J Periodontol 2002: 73: 115-122.
38. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. J Periodontol 1999: 70: 967-972.
39. Jackson C, Babich S. Gingival hyperplasia: interaction between cyclosporin A and nifedipine? A case report N Y State Dent J 1997: 63: 46-48.
40. James JA, Linden GJ. Nifedipine-induced gingival hyperplasia. Dent Update 1992: 19: 440-441.
41. James JA, Marley JJ, Jamal S, Campbell BA, Short CD, Johnson RW, Hull PS, Spratt H, Irwin CR, Boomer S, Maxwell AP, Linden GJ. The calcium channel blocker used with cyclosporin has an effect on gingival overgrowth. J Clin Periodontol 2000: 27: 109-115.
42. Katzung B. Basic and clinical pharmacology, 6th edn. Connecticut: Appleton and Lange, 1995.
43. Khocht A, Schneider LC. Periodontal management of gingival overgrowth in the heart transplant patient: a case report. J Periodontol 1997: 68: 1140-1146.
44. Khoori AH, Einollahi B, Ansari G, Moozeh MB. The effect of cyclosporine with and without nifedipine on gingival overgrowth in renal transplant patients. J Can Dent Assoc 2003: 69: 236-241.
45. Khoshdel A, Attia J, Carney SL. Basic concepts in meta-analysis: a primer for clinicians. Int J Clin Pract 2006: 60: 1287-1294.
46. Kinane DF, Marshall GJ. Periodontal manifestations of systemic disease. Aust Dent J 2001: 46: 2-12.
47. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993: 20: 286-293.
48. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy. Report of a case. Oral Surg Oral Med Oral Pathol 1984: 57: 620-622.
49. Li X, Luan Q, Wang X, Sha Y, He L, Cao C, Jin L. Nifedipine intake increases the risk for periodontal destruction in subjects with type 2 diabetes mellitus. J Periodontol 2008: 79: 2054-2059.
50. MacCarthy D, Claffey N. Fibrous hyperplasia of the gingiva in organ transplant patients. J Ir Dent Assoc 1991: 37: 3-5.
51. Maita E, Sato M, Yamaki K. Effect of tranilast on matrix metalloproteinase-1 secretion from human gingival fibroblasts in vitro. J Periodontol 2004: 75: 1054-1060.
52. Margiotta V, Pizzo I, Pizzo G, Barbaro A. Cyclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, and HLA-antigens. J Oral Pathol Med 1996: 25: 128-134.
53. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992: 63: 453-456.
54. Miranda J, Brunet L, Roset P, Berini L, Farre M, Mendieta C. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol 2001: 72: 605-611.
55. Morgan JD, Swarbrick MJ, Edwards CM, Donnelly PK. Cyclosporin, nifedipine and gingival hyperplasia: a randomized controlled study. Transpl Int 1994: 7(Suppl 1): S320-S321.
56. Naidoo LC, Stephen LX. Nifedipine-induced gingival hyperplasia: non-surgical management of a patient. Spec Care Dentist 1999: 19: 29-34.
57. Nakou M, Kamma JJ, Andronikaki A, Mitsis F. Subgingival microflora associated with nifedipine-induced gingival overgrowth.[Erratum appears in J Periodontol 1999: 70:238]. J Periodontol 1998: 69: 664-669.
58. Naylor CD. Calcium channel antagonists and gingival hyperplasia. Ann Intern Med 1994: 121: 625.
59. Nell A, Matejka M, Solar P, Ulm C, Sinzinger H. Evidence that cyclosporine inhibits periodontal prostaglandin I2 synthesis. J Periodontal Res 1996: 31: 131-134.
60. Nery EB, Edson RG, Lee KK, Pruthi VK, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995: 66: 572-578.
61. Neumann C, Willershausen-Zonnchen B, Klug C, Darius H. Clinical assessment of periodontal conditions in patients treated with nifedipine. Eur J Med Res 1996: 1: 273-279.
62. Newman MG, Caton JG, Gunsolley JC. The use of the evidence-based approach in a periodontal therapy contemporary science workshop. Ann Periodontol 2003: 8: 1-11.
63. Newman MG, Takei HH, Carranza FA. Carranza's clinical periodontology, 10th edn. St Louis, MO: Saunders/Elsevier, 2006.
64. Nishikawa S, Tada H, Hamasaki A, Kasahara S, Kido J, Nagata T, Ishida H, Wakano Y. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991: 62: 30-35.
65. O'Valle F, Mesa F, Aneiros J, Gómez-Morales M, Lucena MA, Ramírez C, Revelles F, Moreno E, Navarro N, Caballero T, Masseroli M, García del Moral R. Gingival overgrowth induced by nifedipine and cyclosporin A. Clinical and morphometric study with image analysis. J Clin Periodontol 1995: 22: 591-597.
66. Payne VM. Re: periodontal management of gingival overgrowth in the heart transplant patient: a case report (1997;68:1140-1146). J Periodontol 1998: 69: 1314-1315.
67. Pilloni A, Camargo PM, Carere M, Carranza FA Jr. Surgical treatment of cyclosporine A- and nifedipine-induced gingival enlargement: gingivectomy versus periodontal flap. J Periodontol 1998: 69: 791-797.
68. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000: 342: 1907-1909.
69. Ramon Y, Behar S, Kishon Y, Engelberg IS. Gingival hyperplasia caused by nifedipine-a preliminary report. Int J Cardiol 1984: 5: 195-206.
70. Rees TD, Levine RA. Systematic drugs as a risk factor for periodontal disease initiation and progression. Compendium 1995: 16: 20, 22, 26 passim; quiz 42.
71. Riley CK, Terezhalmy GT. The patient with hypertension. Quintessence Int 2001: 32: 671-690.
72. Roed-Petersen B. The potential use of CO2-laser gingivectomy for phenytoin-induced gingival hyperplasia in mentally retarded patients. J Clin Periodontol 1993: 20: 729-731.
73. Rossmann JA, Ingles E, Brown RS. Multimodal treatment of drug-induced gingival hyperplasia in a kidney transplant patient. Compendium 1994: 15: 1266, 1268-70, 1272-4; quiz 1276.
74. Sakellari D, Vouros ID, Aristodemou E, Konstantinidis AB, Socransky S, Goodson M. Tetracycline fibers as an adjunct in the treatment of nifedipine-induced gingival enlargement. J Periodontol 2005: 76: 1034-1039.
75. Santi E, Bral M. Effect of treatment on cyclosporine- and nifedipine-induced gingival enlargement: clinical and histologic results. Int J Periodontics Restorative Dent 1998: 18: 80-85.
76. Seymour RA, Preshaw PM, Thomason JM, Ellis JS, Steele JG. Cardiovascular diseases and periodontology. J Clin Periodontol 2003: 30: 279-292.
77. Seymour RA, Thomason JM, Ellis JS. Oral and dental problems in the organ transplant patient. Dent Update 1994: 21: 209-212.
78. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996: 23(3 Pt 1): 165-175.
79. Sheehy EC, Roberts GJ, Beighton D, O'Brien G. Oral health in children undergoing liver transplantation. Int J Paediatr Dent 2000: 10: 109-119.
80. Tavassoli S, Yamalik N, Caglayan F, Caglayan G, Eratalay K. The clinical effects of nifedipine on periodontal status. J Periodontol 1998: 69: 108-112.
81. Thomason JM, Ellis JS, Kelly PJ, Seymour RA. Nifedipine pharmacological variables as risk factors for gingival overgrowth in organ-transplant patients. Clin Oral Invest 1997: 1: 35-39.
82. Thomason JM, Seymour RA, Ellis J. The periodontal problems and management of the renal transplant patient. Ren Fail 1994: 16: 731-745.
83. Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, Idle JR. Iatrogenic gingival overgrowth in cardiac transplantation. J Periodontol 1995: 66: 742-746.
84. Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, Wilkinson R, Ilde JR. Determinants of gingival overgrowth severity in organ transplant patients. An examination of the role of HLA phenotype. J Clin Periodontol 1996: 23: 628-634.
85. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993: 20: 37-40.
86. Westbrook P, Bednarczyk EM, Carlson M, Sheehan H, Bissada NF. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. J Periodontol 1997: 68: 645-650.
87. Wondimu B, Berg U, Modeer T. Renal function in cyclosporine-treated pediatric renal transplant recipients in relation to gingival overgrowth. Transplantation 1997: 64: 92-96.
88. Center for Evidence Based Medicine. Accessed March 1, 2012.
89. Cochrane Oral Health Group: The Cochrane Collaboration. Accessed March 1, 2012.
90. Evidence Based Dentistry. Accessed March 1, 2012.
91. Journal of Evidence Based Dental Practice. Accessed March 1, 2012.
92. SUNY Downstate Medical Center MRLa, Brooklyn. Accessed March 1, 2012.
93. The Cochrane Library. Accessed March 1, 2012.
94. Zhou LX, Pihlstrom B, Hardwick JP, Park SS, Wrighton SA, Holtzman JL. Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin Pharmacol Ther 1996: 60: 191-198.